Abeona Therapeutics (ABEO) |
|
2.75 -0.08 (-2.83%)
|
08-14 16:00 |
|
Open: |
2.83 |
Pre. Close: |
2.83 |
|
High:
|
2.83 |
Low:
|
2.71 |
|
Volume:
|
719,540 |
Market Cap:
|
233M |
|
|
|
|
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.833 - 2.851 |
2.851 - 2.864 |
|
Low:
|
2.669 - 2.69 |
2.69 - 2.706 |
|
Close:
|
2.721 - 2.753 |
2.753 - 2.776 |
|
Technical analysis |
as of: 2020-08-14 4:26:57 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.51 One year: 3.73 |
| Support: |
Support1: 2.71 Support2: 2.25 |
| Resistance: |
Resistance1: 3.01 Resistance2: 3.19 |
| Pivot: |
2.89 |
| Moving Average: |
MA(5): 2.88 MA(20): 2.91
MA(100): 2.79  MA(250): 2.76 |
| MACD: |
MACD(12,26): -0.04 Signal(9): -0.03 |
| Stochastic oscillator: |
%K(14,3): 27.27 %D(3): 38.80 |
| RSI: |
RSI(14): 42.12 |
| 52-week: |
High: 5.19 Low: 1.35 Change(%): 23.3 |
| Average Vol(K): |
3-Month: 85335 10-Days: 53723 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.ABEO has closed above bottom band by 2.9%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to ABEO's normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 12 Aug 2020
Edited Transcript of ABEO earnings conference call or presentation 11-Aug-20 12:30pm GMT - yahoo.com
Wed, 12 Aug 2020
Abeona Therapeutics (ABEO) Gets a Hold Rating from Mizuho Securities - Smarter Analyst
Tue, 11 Aug 2020
Should You Buy Abeona Therapeutics Inc (ABEO) Stock? - InvestorsObserver
Mon, 10 Aug 2020
Abeona Therapeutics: 2Q Earnings Snapshot - Albuquerque Journal
Mon, 10 Aug 2020
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates - GlobeNewswire
Fri, 07 Aug 2020
Need To Know: Abeona Therapeutics Inc. (NASDAQ:ABEO) Insiders Have Been Buying Shares - Simply Wall St
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
84 |
| Shares Float (M) |
70 |
|
% Held by Insiders
|
17.82 |
|
% Held by Institutions
|
66.40 |
|
Shares Short (K)
|
3,040 |
|
Shares Short P. Month (K)
|
2,170 |
Stock Financials |
|
EPS
|
-1.721 |
|
EPS Est This Year
|
-0.700 |
|
EPS Est Next Year
|
-0.770 |
|
Book Value (p.s.)
|
1.580 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-26.9 |
|
Return on Equity (ttm)
|
-84.7 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.581 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.779 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-61 |
|
Levered Free Cash Flow (M)
|
-19 |
Stock Valuations |
|
PE Ratio
|
-1.60 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.74 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-3.77 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
